The bank initiated the clinical-stage biotechnology firm at a buy rating.
Get this delivered to your inbox, and more info about our products and services.
The investment bank upgraded the pharma stock to overweight from equal weight.
Chart analyst Frank Cappelleri breaks down the technical outlook on the biotech stock.
Goldman Sachs sees shares of Biohaven rallying 114% after plunging 72% over the past 12 months.
JPMorgan sees shares of Ultragenyx Pharmaceutical soaring more than 200% from current prices.
The investment firm upgraded the streaming platform to buy from hold.
David Keller breaks down the technicals on this biotech giant.
